Daiichi Told Cancer Drug Patent Fight Must Be Arbitrated
An arbitrator has concluded that a dispute between Daiichi Sankyo Co. Ltd. and a U.S. biotechnology company over cancer drug patents should be arbitrated, saying he was obligated to do so...To view the full article, register now.
Already a subscriber? Click here to view full article